CDR132L explained

CDR132L is an antisense RNA therapy that inhibits MiR-132. It is developed by Cardior Pharmaceuticals to treat heart failure.^{[1] [2] [3]}

Notes and References

1. Batkai . Sandor . Genschel . Celina . Viereck . Janika . Rump . Steffen . Bär . Christian . Borchert . Tobias . Traxler . Denise . Riesenhuber . Martin . Spannbauer . Andreas . Lukovic . Dominika . Zlabinger . Katrin . Hašimbegović . Ena . Winkler . Johannes . Garamvölgyi . Rita . Neitzel . Sonja . Gyöngyösi . Mariann . Thum . Thomas . CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure . European Heart Journal . 7 January 2021 . 42 . 2 . 192–201 . 10.1093/eurheartj/ehaa791. free . 33089304 . 7813625 .
2. Taubel . Jorg . Hauke . Wilfried . Rump . Steffen . Viereck . Janika . Batkai . Sandor . Jenny . Poetzsch . Laura . Rode . Weigt . Henning . Genschel . Celina . Lorch . Ulrike . Theek . Carmen . Levin . Arthur A . Bauersachs . Johann B . Solomon . Scott D . Thum . Thomas . Abstract 114: Safety And Efficacy Of CDR132L, A Novel Antisense Therapeutic Which Targets MicroRNA-132 In Heart Failure Patients . Circulation Research . 3 September 2021 . 129 . Suppl_1 . 10.1161/res.129.suppl_1.114.
3. Täubel . Jörg . Hauke . Wilfried . Rump . Steffen . Viereck . Janika . Batkai . Sandor . Poetzsch . Jenny . Rode . Laura . Weigt . Henning . Genschel . Celina . Lorch . Ulrike . Theek . Carmen . Levin . Arthur A . Bauersachs . Johann . Solomon . Scott D . Thum . Thomas . Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study . European Heart Journal . 11 November 2020 . 42 . 2 . 178–188 . 10.1093/eurheartj/ehaa898 . 0195-668X. free . 33245749 . 7954267 .